Premium
Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer
Author(s) -
Mimura Seishiro,
Ito Yoshiaki,
Nagayo Takeo,
Ichii Makoto,
Kato Harubumi,
Sakai Harumasa,
Goto Kazuo,
Noguchi Yoshiki,
Tanimura Hiroshi,
Nagai Yugo,
Suzuki Shigeru,
Hiki Yoshiki,
Hayata Yoshihiro
Publication year - 1996
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/(sici)1096-9101(1996)19:2<168::aid-lsm7>3.0.co;2-q
Subject(s) - photodynamic therapy , medicine , dye laser , excimer , excimer laser , photosensitivity , cancer , laser , dermatology , surgery , optics , chemistry , optoelectronics , materials science , physics , organic chemistry
Background and Objective Photodynamic therapy (PDT) is a recently developed endoscopic method for treating malignant tumors. For obtaining more photodynamic action with less thermal effect, we employed as the excitation light source for PDT an excimer dye laser, which is a pulsed laser with extremely high peak power, instead of an argon dye laser, which is a continuous wave laser and has been used conventionally. Study Design/Materials and Methods The effect of PDT using Photofrin II and the excimer dye laser was evaluated in 27 patients with early gastric cancer. Results Complete responses (CR) were obtained in 88% of 24 assessable patients and the response rate was 100%. CR was observed in all cases of lesions of superficial depressed type without ulceration and/or with tumor diameter less than 2 cm. Regarding toxicity, mild cutaneous reaction and photosensitivity were seen and lasted several weeks. There were no serious abnormalities in laboratory tests. Conclusion We conclude that PDT is a promising modality for early gastric cancer. © 1996 Wiley‐Liss, Inc.